Mylan N.V. (NASDAQ:MYL)‘s stock had its “buy” rating reiterated by equities researchers at UBS AG in a research note issued to investors on Thursday. They currently have a $46.00 price target on the stock. UBS AG’s price target indicates a potential upside of 21.69% from the stock’s previous close.

Several other research firms have also weighed in on MYL. Zacks Investment Research upgraded shares of Mylan N.V. from a “sell” rating to a “hold” rating in a report on Tuesday, August 1st. Royal Bank Of Canada restated a “hold” rating and issued a $41.00 price objective on shares of Mylan N.V. in a report on Tuesday, June 13th. BidaskClub upgraded shares of Mylan N.V. from a “sell” rating to a “hold” rating in a report on Thursday, June 22nd. Wells Fargo & Company restated a “market perform” rating and issued a $32.00 price objective (up from $30.00) on shares of Mylan N.V. in a report on Wednesday. Finally, Cowen and Company restated a “market perform” rating and issued a $36.00 price objective (up from $30.00) on shares of Mylan N.V. in a report on Thursday. One investment analyst has rated the stock with a sell rating, nine have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $42.04.

Shares of Mylan N.V. (NASDAQ MYL) traded up 0.24% on Thursday, hitting $37.89. 8,433,498 shares of the company were exchanged. Mylan N.V. has a 52-week low of $29.39 and a 52-week high of $45.87. The firm’s 50-day moving average is $31.65 and its 200-day moving average is $36.47. The stock has a market capitalization of $20.32 billion, a PE ratio of 30.63 and a beta of 1.30. Mylan N.V. also saw some unusual options trading activity on Wednesday. Investors purchased 10,562 put options on the stock. This is an increase of approximately 461% compared to the typical volume of 1,883 put options.

Mylan N.V. (NASDAQ:MYL) last announced its quarterly earnings data on Wednesday, August 9th. The company reported $1.10 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.18 by ($0.08). Mylan N.V. had a net margin of 5.51% and a return on equity of 22.42%. The business had revenue of $2.96 billion for the quarter, compared to analysts’ expectations of $3 billion. During the same period in the prior year, the company posted $1.16 EPS. The firm’s revenue was up 15.7% on a year-over-year basis. Equities research analysts predict that Mylan N.V. will post $4.52 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “UBS AG Reaffirms “Buy” Rating for Mylan N.V. (MYL)” was reported by Marea Informative and is the property of of Marea Informative. If you are accessing this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright legislation. The legal version of this piece of content can be read at http://www.mareainformativa.com/ubs-ag-reaffirms-buy-rating-for-mylan-n-v-myl/117865/.

Institutional investors have recently added to or reduced their stakes in the stock. Waldron LP acquired a new position in Mylan N.V. during the first quarter valued at approximately $229,000. UBS Asset Management Americas Inc. lifted its position in Mylan N.V. by 13.7% during the first quarter. UBS Asset Management Americas Inc. now owns 1,179,217 shares of the company’s stock valued at $45,978,000 after buying an additional 142,124 shares in the last quarter. Sei Investments Co. lifted its position in Mylan N.V. by 1.0% during the first quarter. Sei Investments Co. now owns 13,870 shares of the company’s stock valued at $541,000 after buying an additional 134 shares in the last quarter. Blair William & Co. IL lifted its position in Mylan N.V. by 20.3% during the first quarter. Blair William & Co. IL now owns 9,591 shares of the company’s stock valued at $401,000 after buying an additional 1,616 shares in the last quarter. Finally, Alliancebernstein L.P. lifted its position in Mylan N.V. by 4.3% during the first quarter. Alliancebernstein L.P. now owns 822,534 shares of the company’s stock valued at $32,071,000 after buying an additional 33,666 shares in the last quarter. Hedge funds and other institutional investors own 71.97% of the company’s stock.

About Mylan N.V.

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Analyst Recommendations for Mylan N.V. (NASDAQ:MYL)

Receive News & Stock Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related stocks with our FREE daily email newsletter.